Trial Profile
A randomized, double-blind, placebo-controlled, multinational study evaluating the safety and pharmacokinetics of 5 and 10 microg AVE0010 single doses and the efficacy, safety and pharmacokinetics of lixisenatide administered for 5 or 6 weeks, either once or twice daily, following dose escalation from 5 to 30 microg in Japanese and Caucasian type 2 diabetic patients not adequately controlled with sulfonylurea or sulfonylurea and metformin
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2015
Price :
$35
*
At a glance
- Drugs Lixisenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Sanofi-Synthelabo
- 08 Jul 2011 New trial record